Compare $CNSY vs $KTTA | Chartloom

Compare

$CNSY vs $KTTA

Plus Therapeutics Inc · Pasithea Therapeutics Corp

CNSY

Plus Therapeutics Inc

KTTA

Pasithea Therapeutics Corp

Compare $CNSY vs $KTTA

Comparing Plus Therapeutics Inc and Pasithea Therapeutics Corp

CNSYPlus Therapeutics Inc

KTTAPasithea Therapeutics Corp

CNSYPlus Therapeutics Inc

Market cap

$13M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

1.12x

Rev growth (TTM)

—

YTD performance

-45.2%

52W performance

-45.2%

FCF yield

-267.6%

KTTAPasithea Therapeutics Corp

Market cap

$16M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

740.5%

YTD performance

-60.7%

52W performance

-43.0%

FCF yield

-113.8%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CNSY

KTTA

Detailed metrics comparison

CNSY

Plus Therapeutics Inc

KTTA

Pasithea Therapeutics Corp

Market Cap

CNSY$13M

KTTA$16M

Enterprise Value

CNSY$11M

KTTA$-30M

Price

CNSY$1.93

KTTA$0.47

P/E Ratio

CNSYN/A

KTTAN/A

P/S Ratio

CNSY3.16x

KTTA26.84x

EV/Sales

CNSY2.60x

KTTA0.00x

EV/EBITDA

CNSY0.00x

KTTA0.00x

P/B Ratio

CNSY2.22x

KTTA0.32x

P/FCF Ratio

CNSYN/A

KTTAN/A

EV/FCF

CNSY-0.31x

KTTA1.69x

PEG Ratio

CNSYN/A

KTTAN/A

Forward P/E (NTM)

CNSYN/A

KTTAN/A

Forward P/S (NTM)

CNSY1.12x

KTTAN/A

Revenue (TTM)

CNSY$4M

KTTA$0

Revenue Growth (YoY)

CNSYN/A

KTTA740.5%

Forward Rev Growth

CNSY216.6%

KTTA0.0%

Gross Margin (TTM)

CNSY0.0%

KTTA100.5%

Operating Margin (TTM)

CNSY0.0%

KTTA0.0%

EBITDA Margin (TTM)

CNSY-612.0%

KTTA0.0%

Net Margin (TTM)

CNSY-620.7%

KTTA0.0%

FCF Margin (TTM)

CNSY-845.3%

KTTAN/A

Net Income (TTM)

CNSY$-26M

KTTA$-21M

FCF (TTM)

CNSY$-36M

KTTA$-18M

EPS (TTM)

CNSY-$3.78

KTTA-$0.66

ROE (TTM)

CNSY-39417.0%

KTTA-4949.0%

ROA (TTM)

CNSY-15136.0%

KTTA-4681.0%

ROIC (TTM)

CNSY-37414.0%

KTTA-4949.0%

Cash

CNSY$2M

KTTA$46M

Debt

CNSY$0

KTTA$0

Net Cash/Debt

CNSY$2M

KTTA$46M

Current Ratio (TTM)

CNSY1.37x

KTTA26.25x

Quick Ratio (TTM)

CNSY1.26x

KTTA24.91x

Debt/Equity (TTM)

CNSY0.19x

KTTA0.00x

Debt/Assets (TTM)

CNSY0.0%

KTTA0.0%

Interest Coverage (TTM)

CNSYN/A

KTTAN/A

Net Debt/EBITDA (TTM)

CNSY0.00x

KTTA0.00x

Beta

CNSY2.21

KTTA0.39

52W Performance

CNSY-45.2%

KTTA-43.0%

YTD Performance

CNSY-45.2%

KTTA-60.7%

% from 52W High

CNSY-53.6%

KTTA-77.3%

% from 52W Low

CNSY30.0%

KTTA66.4%

Asset Turnover (TTM)

CNSY0.24x

KTTA0.01x

FCF Yield (TTM)

CNSY-267.6%

KTTA-113.8%

Earnings Yield (TTM)

CNSY-196.5%

KTTA-136.3%

Dividend Yield (TTM)

CNSYN/A

KTTAN/A

Rule of 40

CNSY-845.3

KTTA740.5

EV/GP/RG

CNSYN/A

KTTAN/A

Ticker research

View CNSY research View KTTA research

Metric	CNSY Plus Therapeutics Inc	KTTA Pasithea Therapeutics Corp
Market & Valuation
Market Cap	$13M	$16M
Enterprise Value	$11M	$-30M
Price	$1.93	$0.47
P/E Ratio	N/A	N/A
P/S Ratio	3.16x	26.84x
EV/Sales	2.60x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	2.22x	0.32x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.31x	1.69x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	1.12x	N/A
Revenue & Growth
Revenue (TTM)	$4M	$0
Revenue Growth (YoY)	N/A	740.5%
Forward Rev Growth	216.6%	0.0%
Profitability
Gross Margin (TTM)	0.0%	100.5%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-612.0%	0.0%
Net Margin (TTM)	-620.7%	0.0%
FCF Margin (TTM)	-845.3%	N/A
Net Income (TTM)	$-26M	$-21M
FCF (TTM)	$-36M	$-18M
EPS (TTM)	-$3.78	-$0.66
ROE (TTM)	-39417.0%	-4949.0%
ROA (TTM)	-15136.0%	-4681.0%
ROIC (TTM)	-37414.0%	-4949.0%
Financial Health
Cash	$2M	$46M
Debt	$0	$0
Net Cash/Debt	$2M	$46M
Current Ratio (TTM)	1.37x	26.25x
Quick Ratio (TTM)	1.26x	24.91x
Debt/Equity (TTM)	0.19x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.21	0.39
52W Performance	-45.2%	-43.0%
YTD Performance	-45.2%	-60.7%
% from 52W High	-53.6%	-77.3%
% from 52W Low	30.0%	66.4%
Efficiency & Yields
Asset Turnover (TTM)	0.24x	0.01x
FCF Yield (TTM)	-267.6%	-113.8%
Earnings Yield (TTM)	-196.5%	-136.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-845.3	740.5
EV/GP/RG	N/A	N/A
Ticker research	View CNSY research	View KTTA research

Valuation

P/S Ratio

CNSY

3.16x

KTTA

26.84x

EV/FCF

CNSY

-0.31x

KTTA

1.69x

Growth & revenue

Revenue Growth TTM

KTTA

740.5%

Forward Revenue Growth

CNSY

216.6%

KTTA

0.0%

Profitability & performance

Gross Margin

KTTA

100.5%

CNSY

0.0%

ROE

KTTA

-4949.0%

CNSY

-39417.0%

FCF Yield %

KTTA

-113.8%

CNSY

-267.6%

52-Week Performance

KTTA

-43.0%

CNSY

-45.2%

Detailed metrics comparison

CNSY

Plus Therapeutics Inc

KTTA

Pasithea Therapeutics Corp

Market Cap

CNSY$13M

KTTA$16M

Enterprise Value

CNSY$11M

KTTA$-30M

Price

CNSY$1.93

KTTA$0.47

P/E Ratio

CNSYN/A

KTTAN/A

P/S Ratio

CNSY3.16x

KTTA26.84x

EV/Sales

CNSY2.60x

KTTA0.00x

EV/EBITDA

CNSY0.00x

KTTA0.00x

P/B Ratio

CNSY2.22x

KTTA0.32x

P/FCF Ratio

CNSYN/A

KTTAN/A

EV/FCF

CNSY-0.31x

KTTA1.69x

PEG Ratio

CNSYN/A

KTTAN/A

Forward P/E (NTM)

CNSYN/A

KTTAN/A

Forward P/S (NTM)

CNSY1.12x

KTTAN/A

Revenue (TTM)

CNSY$4M

KTTA$0

Revenue Growth (YoY)

CNSYN/A

KTTA740.5%

Forward Rev Growth

CNSY216.6%

KTTA0.0%

Gross Margin (TTM)

CNSY0.0%

KTTA100.5%

Operating Margin (TTM)

CNSY0.0%

KTTA0.0%

EBITDA Margin (TTM)

CNSY-612.0%

KTTA0.0%

Net Margin (TTM)

CNSY-620.7%

KTTA0.0%

FCF Margin (TTM)

CNSY-845.3%

KTTAN/A

Net Income (TTM)

CNSY$-26M

KTTA$-21M

FCF (TTM)

CNSY$-36M

KTTA$-18M

EPS (TTM)

CNSY-$3.78

KTTA-$0.66

ROE (TTM)

CNSY-39417.0%

KTTA-4949.0%

ROA (TTM)

CNSY-15136.0%

KTTA-4681.0%

ROIC (TTM)

CNSY-37414.0%

KTTA-4949.0%

Cash

CNSY$2M

KTTA$46M

Debt

CNSY$0

KTTA$0

Net Cash/Debt

CNSY$2M

KTTA$46M

Current Ratio (TTM)

CNSY1.37x

KTTA26.25x

Quick Ratio (TTM)

CNSY1.26x

KTTA24.91x

Debt/Equity (TTM)

CNSY0.19x

KTTA0.00x

Debt/Assets (TTM)

CNSY0.0%

KTTA0.0%

Interest Coverage (TTM)

CNSYN/A

KTTAN/A

Net Debt/EBITDA (TTM)

CNSY0.00x

KTTA0.00x

Beta

CNSY2.21

KTTA0.39

52W Performance

CNSY-45.2%

KTTA-43.0%

YTD Performance

CNSY-45.2%

KTTA-60.7%

% from 52W High

CNSY-53.6%

KTTA-77.3%

% from 52W Low

CNSY30.0%

KTTA66.4%

Asset Turnover (TTM)

CNSY0.24x

KTTA0.01x

FCF Yield (TTM)

CNSY-267.6%

KTTA-113.8%

Earnings Yield (TTM)

CNSY-196.5%

KTTA-136.3%

Dividend Yield (TTM)

CNSYN/A

KTTAN/A

Rule of 40

CNSY-845.3

KTTA740.5

EV/GP/RG

CNSYN/A

KTTAN/A

Ticker research

View CNSY research View KTTA research

Metric	CNSY Plus Therapeutics Inc	KTTA Pasithea Therapeutics Corp
Market & Valuation
Market Cap	$13M	$16M
Enterprise Value	$11M	$-30M
Price	$1.93	$0.47
P/E Ratio	N/A	N/A
P/S Ratio	3.16x	26.84x
EV/Sales	2.60x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	2.22x	0.32x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.31x	1.69x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	1.12x	N/A
Revenue & Growth
Revenue (TTM)	$4M	$0
Revenue Growth (YoY)	N/A	740.5%
Forward Rev Growth	216.6%	0.0%
Profitability
Gross Margin (TTM)	0.0%	100.5%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-612.0%	0.0%
Net Margin (TTM)	-620.7%	0.0%
FCF Margin (TTM)	-845.3%	N/A
Net Income (TTM)	$-26M	$-21M
FCF (TTM)	$-36M	$-18M
EPS (TTM)	-$3.78	-$0.66
ROE (TTM)	-39417.0%	-4949.0%
ROA (TTM)	-15136.0%	-4681.0%
ROIC (TTM)	-37414.0%	-4949.0%
Financial Health
Cash	$2M	$46M
Debt	$0	$0
Net Cash/Debt	$2M	$46M
Current Ratio (TTM)	1.37x	26.25x
Quick Ratio (TTM)	1.26x	24.91x
Debt/Equity (TTM)	0.19x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.21	0.39
52W Performance	-45.2%	-43.0%
YTD Performance	-45.2%	-60.7%
% from 52W High	-53.6%	-77.3%
% from 52W Low	30.0%	66.4%
Efficiency & Yields
Asset Turnover (TTM)	0.24x	0.01x
FCF Yield (TTM)	-267.6%	-113.8%
Earnings Yield (TTM)	-196.5%	-136.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-845.3	740.5
EV/GP/RG	N/A	N/A
Ticker research	View CNSY research	View KTTA research